# ImStar Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imstar-therapeutics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.imstartx.com
- Total disclosed funding: $1.8M
- Latest round: Seed (Jun 8, 2016)
- Investors on record: 3

## About

ImStar Therapeutics is a biotechnology company focused on developing innovative therapies aimed at addressing unmet medical needs. Their work primarily revolves around enhancing patient outcomes through advanced treatment options.ImStar Therapeutics is engaged in the development of biopharmaceutical products. Founded in 2012 and headquartered in Vancouver, Canada, the company has undergone no significant pivots in its business strategy. The company's latest funding round occurred in June 2016, when it raised USD 1.8 mn in a SEED round co-led by Accel-Rx Health Sciences Accelerator and BDC Capital, with participation from AviTx Inc. and individual investors. The total amount raised by the company to date is USD 1.8 mn.The company offers a diverse range of products designed to address specific needs within its target markets. Central to its offerings is a flagship product, engineered to enhance operational efficiency for businesses in various sectors. This product is equipped with advanced technology that streamlines processes, leading to improved productivity and cost savings for end users. ImStar Therapeutics primarily serves medium to large enterprises across industries such as manufacturing, logistics, and retail, with a strong market presence in North America and Europe.The company's revenue structure is based on a subscription model, allowing clients to access its services on a recurring basis. This framework generally involves annual or monthly contracts, providing clients with flexibility. Pricing plans are tiered to accommodate varying customer needs, ensuring that both small businesses and large corporations can benefit from the company's offerings. Furthermore, flagship products are typically bundled with additional services, enhancing their overall value proposition, while partnerships with retailers and distributors help extend their reach to a broad array of end users.ImStar Therapeutics is focused on expanding its product line with new therapies that are currently in development, aiming for release in the coming years. The company also plans to enter new markets, specifically targeting Europe and Asia by 2025. The recent SEED funding of USD 1.8 mn will be utilized to support these initiatives, enhancing research and development capabilities and facilitating market entry strategies.

## Funding rounds

- Seed, Jun 8, 2016, $1.8M — BDC Capital, Accel-Rx Health Sciences Accelerator, AviTx Inc.

## Investors

- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Seed
- Accel-Rx Health Sciences Accelerator — Seed
- AviTx Inc. — Seed